1. Show article details.

    BRIEF-Chromadex Partners With Personalized Nutrition Company, Persona Nutrition, Expanding Global Partnership With Nestlé Health Science

    Reuters – 7:33 AM ET 02/12/2020

    Chromadex Corp (CDXC): * CHROMADEX PARTNERS WITH PERSONALIZED NUTRITION COMPANY, PERSONA NUTRITION, EXPANDING GLOBAL PARTNERSHIP WITH NESTLÉ HEALTH SCIENCE Source text for Eikon: Further company coverage:

  2. Show article details.

    ChromaDex Partners with Personalized Nutrition Company, Persona Nutrition, Expanding Global Partnership with Nestlé Health Science

    GlobeNewswire – 6:30 AM ET 02/12/2020

    ChromaDex Corp. (CDXC) today announced the launch of its flagship cellular health supplement Tru Niagen® as a supplement offering in Nestlé Health Science’s personalized nutrition service – Persona Nutrition.

  3. Show article details.

    ChromaDex Launches New Line of High Purity Cannabinoid (CBD) Reference Standards Available for Research and Analytical Testing Worldwide

    GlobeNewswire – 6:30 AM ET 02/03/2020

    ChromaDex Corp. (CDXC) today announced the expansion of its industry-leading reference standards business with a new line of cannabinoid reference standards available to researchers across the globe.

  4. Show article details.

    BRIEF-Chromadex Achieves New Regulatory Milestones In The European Union & Australia

    Reuters – 6:50 AM ET 01/15/2020

    Chromadex Corp (CDXC): * CHROMADEX ACHIEVES NEW REGULATORY MILESTONES IN THE EUROPEAN UNION & AUSTRALIA. * CHROMADEX (CDXC) - ANNOUNCED REGULATORY AUTHORIZATIONS TO SELL ITS PATENTED NICOTINAMIDE RIBOSIDE CHLORIDE TO CONSUMERS IN BOTH EU & IN AUSTRALIA Source text for Eikon: Further company coverage:

  5. Show article details.

    ChromaDex Achieves New Regulatory Milestones in the European Union & Australia

    GlobeNewswire – 6:30 AM ET 01/15/2020

    ChromaDex Corp. (CDXC) today announced regulatory authorizations to sell its patented nicotinamide riboside chloride to consumers in both the European Union and in Australia. ChromaDex (CDXC) received its listing number for Tru Niagen® on the Australian Registry of Therapeutic Goods on January 8, 2020.

  6. Show article details.

    First-of-its-Kind Clinical Study Initiated to Investigate Potential Benefits of Nicotinamide Riboside Combined with Exercise in Older Adults with Hypertension

    GlobeNewswire – 6:30 AM ET 01/06/2020

    ChromaDex Corp. (CDXC), the global scientific authority on nicotinamide adenine dinucleotide and nicotinamide riboside science, announced today the initiation of a first-of-its-kind Phase 1 clinical study sponsored by the University of Florida, in collaboration with the National Institute on Aging.

  7. Show article details.

    ChromaDex Wins Nutritional Outlook’s 2019 “Best of Industry” Ingredient Supplier Award for Niagen®

    GlobeNewswire – 6:30 AM ET 12/16/2019

    ChromaDex Corp. (CDXC) announced today that Nutritional Outlook®, a leading publication for the nutraceuticals industry, recently awarded ChromaDex (CDXC) the 2019 “Best of Industry Award,” in the “Ingredient Supplier” category, for Niagen®.  The state of the science surrounding Niagen will be presented during the ChromaDex Scientific Advisory Board annual meeting taking place Dec. 16-17 in Los Angeles, CA. ...

  8. Show article details.

    BRIEF-ChromaDex Launches Tru Niagen Pro 500

    Reuters – 7:12 AM ET 12/11/2019

    Chromadex Corp (CDXC): * CHROMADEX LAUNCHES TRU NIAGEN® PRO 500, THE LARGEST SERVING OF PATENTED NICOTINAMIDE RIBOSIDE AVAILABLE WORLDWIDE. * Chromadex Corp (CDXC) - TRU NIAGEN PRO 500 WILL BE AVAILABLE EXCLUSIVELY THROUGH LICENSED HEALTHCARE PRACTITIONERS IN UNITED STATES Source text for Eikon: Further company coverage:

  9. Show article details.

    ChromaDex Launches Tru Niagen® Pro 500, the Largest Serving of Patented Nicotinamide Riboside Available Worldwide

    GlobeNewswire – 6:30 AM ET 12/11/2019

    ChromaDex Corp. (CDXC) today announced the launch of Tru Niagen® Pro 500, the largest daily serving of its patented nicotinamide riboside ingredient in the world. “This new product will allow practitioners to provide a unique product to their patients who want more energy and improved cellular health,” says ChromaDex CEO Rob Fried.

  10. Show article details.

    BRIEF-Chromadex And Matakana Announce Expanded Retail Partnership In Australia & New Zealand

    Reuters – 6:36 AM ET 12/05/2019

    Chromadex Corp (CDXC): * CHROMADEX AND MATAKANA ANNOUNCE EXPANDED RETAIL PARTNERSHIP IN AUSTRALIA & NEW ZEALAND. * Chromadex Corp (CDXC) - EXPANSION OF ITS PARTNERSHIP WITH MATAKANA HEALTH UNTIL EARLY 2023, WHICH WILL NOW INCLUDE AUSTRALIA IN ITS TERRITORY Source text for Eikon: Further company coverage:

  11. Show article details.

    ChromaDex and Matakana Announce Expanded Retail Partnership in Australia & New Zealand

    GlobeNewswire – 6:30 AM ET 12/05/2019

    ChromaDex Corp. (CDXC) announced today the expansion of its partnership with Matakana Health until early 2023, which will now include Australia in its territory. MHL is an established dietary supplement manufacturer and distributor in New Zealand with national and Australian distribution in both online and offline channels.

  12. Show article details.

    ChromaDex Receives Approval for Nicotinamide Riboside Chloride as an Ingredient for Complementary Medicines from the Australian Therapeutic Goods Administration (TGA)

    GlobeNewswire – 6:30 AM ET 12/02/2019

    ChromaDex Corp.  today announced that it has received approval from the Australian Therapeutic Goods Administration for its patented nicotinamide riboside chloride for use in listed complementary medicines. With this approval, ChromaDex (CDXC) will be listing their final product as a complementary medicine on the Australian Register of Therapeutic Goods.

  13. Show article details.

    European Commission Votes in Favor on Nicotinamide Riboside Chloride as a Novel Food

    GlobeNewswire – 6:30 AM ET 11/20/2019

    ChromaDex Corp. (CDXC) today announced that European Member States have voted in favor of listing Nicotinamide Riboside Chloride as a novel food ingredient at a daily serving of 300mg for the healthy adult population. This approval follows a positive opinion issued by the European Food Safety Authority in August 2019.

  14. Show article details.

    ChromaDex Corporation Reports Third Quarter 2019 Financial Results   

    GlobeNewswire – 4:01 PM ET 11/12/2019

    Third Quarter 2019 Highlights vs. LOS ANGELES, Nov. 12, 2019 -- ChromaDex Corp. (CDXC) today reported third quarter 2019 financial results. “We had another strong quarter with total net sales of $12.1 million, up 9% sequentially and 48% year-over-year,” said ChromaDex CEO Rob Fried.

  15. Show article details.

    ChromaDex to Report Third Quarter 2019 Financial Results on Tuesday, November 12, 2019

    GlobeNewswire – 6:30 AM ET 11/04/2019

    ChromaDex Corp.  announced that it will hold a conference call on Tues., Nov. 12, 2019 at 4:30 p.m. ET to discuss its financial results for the third quarter ended Sept. 30, 2019. Investor Conference Call: ChromaDex management will host an investor conference call to discuss the third quarter results and provide a general business update on Tues., Nov. 12, at 4:30 p.m. ET.

  16. Show article details.

    Tru Niagen® Wins ‘Most Favourite Brand’ Award Among Watsons Hong Kong Loyalty Members

    GlobeNewswire – 6:30 AM ET 10/31/2019

    ChromaDex Corp. (CDXC) announced today its Tru Niagen® product was recognized as “MoneyBack Members’ Most Favourite Brand” at the Health, Wellness & Beauty Awards 2019 held in Hong Kong on October 24.

  17. Show article details.

    New Study Demonstrates a Unique Role of Nicotinamide Riboside Over Other NAD Precursors

    GlobeNewswire – 6:30 AM ET 10/17/2019

    ChromaDex Corp. (CDXC) announced today that the  results of a preclinical study conducted by Nestlé were published last month in the journal Nature Communications, a peer-reviewed open access scientific journal published by the Nature Publishing Group. The study investigated the impact on the liver when its cells lose the ability to use the nutrient nicotinamide riboside.

  18. Show article details.

    ChromaDex Statement Regarding the October 9th Order in the Central District of California Litigation

    GlobeNewswire – 6:30 AM ET 10/11/2019

    ChromaDex Corp.  issued the following statement. We would like to take this opportunity to comment on the latest order from the California court regarding the ongoing litigation with Elysium. In his order, the judge seeks additional information about how ChromaDex (CDXC) was damaged by the theft, and we look forward to answering his questions.

  19. Show article details.

    Humanitarian Grant Awarded for Preclinical Study on the Impact of NAD Precursor Vitamins on Milk Bioactive Production and Brain Development in Rodents

    GlobeNewswire – 6:30 AM ET 10/07/2019

    Dr. Charles Brenner, the Roy J. Carver Chair and Head of Biochemistry at the University of Iowa, receives a research grant from the Bill & Melinda Gates Foundation to study the effects of NAD-boosting supplements on the production of bioactive factors in milk and the effect of the supplements on brain development in animals.

  20. Show article details.

    ChromaDex to Present at the 5th Annual B. Riley FBR Consumer and Media Conference

    GlobeNewswire – 6:30 AM ET 09/26/2019

    ChromaDex Corp.  announced today that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Kevin Farr, will present at the 5th Annual B. Riley FBR Consumer and Media Conference at the Sofitel Hotel in New York, NY. The ChromaDex management team is scheduled to present on Thursday, October 3, 2019 at 2:00 p.m. Eastern Time.

Page:

Today's and Upcoming Events

  • Mar
    09

    CDXC to announce Q4 earnings (Unconfirmed)

Past Events (last 90 days)

  • Nov
    12

    CDXC announced Q3 earnings.

Data provided by Thomson Reuters © 2020

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.